2.83

2.91% 0.08

After Hours: 2.72 -0.11 -3.89%

Prime Medicine Inc (PRME)

Overview News Price History Option Chain Financials Discussions Forecast

Prime Medicine Inc stock is traded at $2.83, with a volume of 616.07K. It is up +2.91% in the last 24 hours and up +1.80% over the past month. Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Previous Close:

$2.75

Open:

$2.83

24h Volume:

616.07K

Relative Volume:

0.58

Market Cap:

$371.19M

Revenue:

Net Income/Loss:

$-217.44M

P/E Ratio:

-1.3041

EPS:

-2.17

Net Cash Flow:

$-205.20M

1W Performance:

-13.19%

1M Performance:

+1.80%

6M Performance:

-47.88%

1Y Performance:

-58.32%

1-Day Range:

$2.765

$2.92

1-Week Range:

$2.70

$3.34

52-Week Range:

$2.56

$9.77

Prime Medicine Inc Stock (PRME) Company Profile

Name

Prime Medicine Inc

Sector

Healthcare (1174)

Industry

Biotechnology (678)

Phone

617-465-0013

Address

60 FIRST ST., CAMBRIDGE

Employee

234

Twitter

Next Earnings Date

Latest SEC Filings

PRME's Discussions on Twitter

Compare PRME with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRME Prime Medicine Inc	2.83	371.19M	0	-217.44M	-205.20M	-2.17
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-24	Initiated	JMP Securities	Mkt Outperform
May-20-24	Initiated	H.C. Wainwright	Buy
May-16-24	Upgrade	Citigroup	Neutral → Buy
Apr-22-24	Initiated	Chardan Capital Markets	Buy
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform
Jan-16-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Initiated	Citigroup	Neutral
Oct-09-23	Initiated	BMO Capital Markets	Outperform
Jul-31-23	Initiated	Guggenheim	Buy
Apr-18-23	Initiated	Stifel	Buy
Nov-14-22	Initiated	Goldman	Neutral
Nov-14-22	Initiated	JP Morgan	Overweight
Nov-14-22	Initiated	Jefferies	Buy
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight

View All

Prime Medicine Inc Stock (PRME) Latest News

12:29 PM

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm -January 30, 2025 at 12:27 pm EST - Marketscreener.com

12:29 PM

12:26 PM

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PR Newswire

12:26 PM

07:59 AM

Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

07:59 AM

Jan 24, 2025

Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace

Jan 24, 2025

Jan 20, 2025

Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jan 20, 2025

Jan 15, 2025

Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jan 13, 2025

Jan 08, 2025

Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World

Jan 08, 2025

Jan 07, 2025

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Jan 07, 2025

Prime Medicine (NYSE:PRME) Rating Increased to Sell at StockNews.com - Defense World

Jan 07, 2025

Jan 06, 2025

Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat

Jan 06, 2025

Jan 05, 2025

Prime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by Brokerages - MarketBeat

Jan 05, 2025

Geode Capital Management LLC Has $5.26 Million Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jan 05, 2025

Barclays PLC Boosts Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Jan 05, 2025

Dec 31, 2024

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Insider Monkey

Dec 31, 2024

Dec 30, 2024

Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey

Dec 30, 2024

State Street Corp Buys 43,086 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World

Dec 30, 2024

Dec 29, 2024

12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey

Dec 29, 2024